2015
DOI: 10.1002/hup.2463
|View full text |Cite
|
Sign up to set email alerts
|

Improved working memory performance following administration of a single dose of American ginseng (Panax quinquefolius L.) to healthy middle‐age adults

Abstract: These data confirm that P. quinquefolius can acutely benefit working memory and extend the age range of this effect to middle-aged individuals. These changes are unlikely to be underpinned by modulation of blood glucose in this population.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
37
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 47 publications
(40 citation statements)
references
References 53 publications
3
37
0
Order By: Relevance
“…This led us to evaluate the effects of 200 mg of the same extract in healthy, middle‐aged adults. We again observed enhanced working memory in the 6 h following administration (Ossoukhova et al, 2015). A composite working memory battery was significantly improved and maximal 3 h post‐dose.…”
Section: Introductionsupporting
confidence: 62%
“…This led us to evaluate the effects of 200 mg of the same extract in healthy, middle‐aged adults. We again observed enhanced working memory in the 6 h following administration (Ossoukhova et al, 2015). A composite working memory battery was significantly improved and maximal 3 h post‐dose.…”
Section: Introductionsupporting
confidence: 62%
“…Regarding the effect of P. ginseng on cognition, Geng et al (2010) published an extensive systematic review which included nine randomized, double-blind, placebo-controlled studies (eight of which enrolled healthy participants) and concluded there was no convincing evidence to support the cognitive enhancing effect of ginseng. Following this report, additional clinical studies in literature described the beneficial effects of Cereboost™ (100e400 mg per os) on the short-term working memory performance in both 52 middle-aged healthy adults (Ossoukhova et al, 2015) and 32 healthy young adults (Scholey et al, 2010). Although these Authors did not provide any direct evidence about the mechanism(s) underlying the nootropic effect of Cereboost™, they speculated a possible role for the activation of both cholinergic and dopaminergic brain systems and modulation of NO production.…”
Section: Clinical Studiesmentioning
confidence: 91%
“…Rg1 can also improve nonspecific immunity in humans and promote the hematopoietic and immune function recovery of patients with bone marrow injury; thus, this molecule can be used to treat various immune and hematopoietic system diseases (Lee et al, 2004;Xu et al, 2012). Simultaneously, five clinical trials on the use of drugs containing Rg1 to treat vascular dementia, cognitive changes, Sjögren's syndrome, rheumatic diseases, and stroke, as well as a safety evaluation, have been registered on clinicaltrials.gov; three of these trials have completed recruitment, and the related results have been published; two have not yet completed subject recruitment (Sotaniemi et al, 1995;Ellis and Reddy, 2002;Scholey et al, 2010;Ossoukhova et al, 2015;Shin et al, 2016;Tian et al, 2016).…”
Section: Introductionmentioning
confidence: 99%